Table 2 Overview of treatment characteristics and outcomes

	1 (20 µg) n = 6	2 (40 µg) n = 7	3 (100 µg) n = 7	4 (100 µg + pembrolizumab) n = 6	Total n = 26
Median number of administered TEIPP24 vaccinations [range]	3 [2,3]^a	3 [2,3]^a	3 [2,3]^a	3	3 [2,3]
Number of patients with all 3 vaccinations	5	6	6	6	23
DLT	0	0	0	0	0
SAE (patients)	3	3	2	1	9
SUSAR	0	0	0	0	0
Clinical response at week 9^b
CR	0	0	0	0	0
PR	1	0	0	0	1
SD	2	2	1	3	8
PD	3^c	5^d	6^e	3^c	17

DLT dose limiting toxicity, OS overall survival, SAE serious adverse event, SUSAR suspected unexpected serious adverse reaction.
^aOne patient received only two TEIPP24 vaccinations due to rapid clinical deterioration or radiographic progression.
^bAccording to RECIST 1.1 for patients that underwent radiological response evaluation according to protocol. PD progressive disease, SD stable disease, PR partial response, CR complete response.
^cFor two of these patients radiological response evaluation was performed after the second TEIPP24 vaccination due to clinical deterioration. Two of these patients had mixed response.
^dFor one of these patients radiologic response evaluation was performed after the first TEIPP24 vaccination due to clinical deterioration, for one patient PD was based on cerebral metastases, no new CT thorax and abdomen was performed.
^eFor one of these patients radiological response evaluation was performed after the second TEIPP24 vaccination due to rapid progressive disease.

Quick links

Search